0001549595-24-000081.txt : 20240613 0001549595-24-000081.hdr.sgml : 20240613 20240613183934 ACCESSION NUMBER: 0001549595-24-000081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240613 FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ring Christine CENTRAL INDEX KEY: 0001817199 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39398 FILM NUMBER: 241042564 MAIL ADDRESS: STREET 1: C/O NURIX THERAPEUTICS, INC. STREET 2: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nurix Therapeutics, Inc. CENTRAL INDEX KEY: 0001549595 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270838048 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: (415) 660-5320 MAIL ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: Nurix, Inc. DATE OF NAME CHANGE: 20120509 4 1 wk-form4_1718318368.xml FORM 4 X0508 4 2024-06-13 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817199 Ring Christine C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Legal Officer 1 Common Stock 2024-06-13 4 M 0 1864 1.86 A 21702 D Common Stock 2024-06-13 4 S 0 1864 17.0178 D 19838 D Employee Stock Option (right to buy) 1.86 2024-06-13 4 M 0 1864 0 D 2029-09-30 Common Stock 1864 94306 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.07. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. /s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring 2024-06-13